Trial · NCT00501059
Results by group116
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 116
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 1% subjects had an efficacy event | 528 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Placebo | Days until 1% subjects had an efficacy event | 381 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 2% subjects had an efficacy event | 889 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Placebo | Days until 2% subjects had an efficacy event | 796 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 3% subjects had an efficacy event | 1225 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Placebo | Days until 3% subjects had an efficacy event | 1134 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 4% subjects had an efficacy event | 1630 | Days | |
| Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack) | Placebo | Days until 4% subjects had an efficacy event | 1582 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 1% subjects had an efficacy event | 678 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Placebo | Days until 1% subjects had an efficacy event | 522 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 2% subjects had an efficacy event | 1167 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Placebo | Days until 2% subjects had an efficacy event | 1053 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 3% subjects had an efficacy event | 1599 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Placebo | Days until 3% subjects had an efficacy event | 1501 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 4% subjects had an efficacy event | 1949 | Days | |
| Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown) | Placebo | Days until 4% subjects had an efficacy event | 1930 | Days | |
| Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 1% subjects had non-fatal MI | 1309 | Days | |
| Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA | Placebo | Days until 1% subjects had non-fatal MI | 1085 | Days | |
| Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA | Acetylsalicylic Acid (Aspirin, BAYE4465) | Days until 2% subjects had non-fatal MI | NA | Days | |
| Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA | Placebo | Days until 2% subjects had non-fatal MI | 2121 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00501059/results